CMS To Use Coverage With Evidence Development When Rx Benefit Is Likely
Executive Summary
The Centers for Medicare & Medicaid Services will use coverage with evidence development only when an agent is highly likely to show benefit in a broader patient population than its labeled indication, CMS Senior Advisor Peter Bach said Dec. 5
You may also be interested in...
CMS Working On Coverage With Evidence Development Despite Scrutiny
CMS "hopes to issue" a revised draft guidance document on coverage with evidence development (CED) in the spring or summer of 2006, according to Tamara Syrek Jensen, deputy director of CMS' coverage and analysis group
CMS Working On Coverage With Evidence Development Despite Scrutiny
CMS "hopes to issue" a revised draft guidance document on coverage with evidence development (CED) in the spring or summer of 2006, according to Tamara Syrek Jensen, deputy director of CMS' coverage and analysis group
FDA, CMS Data-Sharing Gets Jump Start With Biomarker Initiative
The Oncology Biomarker Qualification Initiative could serve as a pilot test for further data collaboration between FDA and CMS